Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

Synthesis and characterization of [18F]mG2P026 as a high contrast PET imaging ligand for metabotropic glutamate receptor 2

Gengyang Yuan, Maeva Dhaynaut, Nicolas Guehl, Sung-Hyun Moon, Xiying Qu, Sepideh Afshar, Georges El Fakhri, Marc Normandin and Anna-Liisa Brownell
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 11;
Gengyang Yuan
1Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maeva Dhaynaut
1Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Guehl
1Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sung-Hyun Moon
1Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiying Qu
1Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sepideh Afshar
1Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georges El Fakhri
1Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Normandin
1Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna-Liisa Brownell
1Gordon Center for Medical Imaging, Massachusetts General Hospital and Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

11

Objectives: Metabotropic glutamate receptor 2 (mGluR2) is presynaptically expressed in neurons and astrocytes where it modulates the synaptic transmission and participates in synaptic plasticity. Activation of this receptor via positive allosteric modulators (PAMs) represents an attractive strategy in enhancing mGluR2 function. Although several PAMs showed promising results in preclinical animal models, the clinical proof of concept is still absent. The current work aims to develop a high contrast positron emission tomography (PET) imaging ligand to elucidate the mGluR2 neurobiology in vivo and promote the drug discovery on PAMs.

Methods: An array of triazolopyridines were synthesized as potential mGluR2 PAMs and their structure-activity relationship (SAR) was analyzed. The best candidate mG2P026 was radiolabeled via the Cu(I)-mediated radiofluorination of organoboranes in the TRACERLabTM FXFN module. Characterization of [18F]mG2P026 was first conducted in Sprague-Dawley rats. The binding specificity of [18F]mG2P026 was tested by the pretreatment of three structurally distinct PAMs, i.e., mG2P001, BINA and mG2P026, before tracer injection. The following PET studies in cynomolgus monkeys investigated the binding profile of [18F]mG2P026 across different brain areas. The arterial blood was sampled to characterize the radiometabolite and provide input function for quantitative modeling. One-, two-tissue compartment models and Logan plot were investigated to generate reliable regional total volume of distribution (VT).

Results: mG2P026 was a potent mGluR2 PAM (EC50 = 12 nM) with an apparent mGluR2 agonist activity (IC50 = 102 nM). Synthesis of [18F]mG2P026 was achieved with good radiochemical yield (RCY = 12 ± 4%, non-decay-corrected) and excellent chemical and radiochemical purities (> 95%) at the end of synthesis (EOS, 55 min, n > 5). In rats, [18F]mG2P026 distributed in the mGluR2-expressing regions of striatum, thalamus, cortex, hypothalamus, hippocampus and cerebellum. All the blocking experiments, however, showed enhanced PET signals, the extent of which varied by the class of injected PAMs. Specifically, the self-blocking elicited the most enhancement, which was similar under two different doses (2.0 mg/kg versus 4.0 mg/kg). The mG2P001 showed a lower enhancement than mG2P026. Interestingly, although BINA had the least enhancement, it showed a dose-dependent characteristic, where a higher dose (2 mg/kg) led to a higher increase across the brain regions of interest than those at a lower dose (1 mg/kg) except in the cortex. In the primate studies, the metabolite chromatogram revealed a moderate in vivo stability of [18F]mG2P026 with the presence of two more polar radiometabolites. The time-activity curves (TACs) were well described via the two-tissue compartment model (2T4k1v) and the Logan plot linearized well. A comparison of the PET SUV images between [18F]mG2P026 and our recently published [18F]JNJ-46356479 at the time window from 30 to 60 min further demonstrated the superior binding profile of [18F]mG2P026 for imaging mGluR2.

Conclusions: We have identified a potent mGluR2 ago-PAM mG2P026 from the SAR study of the triazolopyridines. mG2P026 can be radiolabeled via fluorine-18 in the automated synthetic module. Preclinical studies in rats demonstrated the unique feature of structurally distinct mGluR2 PAMs in affecting the radioactivity uptake of [18F]mG2P026. Further imaging studies in primates revealed the excellent contrast of [18F]mG2P026 in mapping the mGluR2 distribution in the brain. Acknowledgement: The research was supported by NIH grants [1R01EB021708, 1R01NS100164, 1S10RR023452-01 and 1S10OD025234-01]. The NIH grants [S10OD018035 and P41EB022544] supported the blood counting and metabolite analysis equipment used in the primate studies.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Synthesis and characterization of [18F]mG2P026 as a high contrast PET imaging ligand for metabotropic glutamate receptor 2
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Synthesis and characterization of [18F]mG2P026 as a high contrast PET imaging ligand for metabotropic glutamate receptor 2
Gengyang Yuan, Maeva Dhaynaut, Nicolas Guehl, Sung-Hyun Moon, Xiying Qu, Sepideh Afshar, Georges El Fakhri, Marc Normandin, Anna-Liisa Brownell
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 11;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synthesis and characterization of [18F]mG2P026 as a high contrast PET imaging ligand for metabotropic glutamate receptor 2
Gengyang Yuan, Maeva Dhaynaut, Nicolas Guehl, Sung-Hyun Moon, Xiying Qu, Sepideh Afshar, Georges El Fakhri, Marc Normandin, Anna-Liisa Brownell
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 11;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Spleen targeting H2S donating liposome as theranostic immune modulator in dextran sodium sulfate induced colitis model
  • Imaging non-coding microRNA upregulation in pressure overload heart failure using the complementary anti-miR-21 locked nucleic acid
  • Human Research Studies on the PennPET Explorer
Show more Oral - PhysicianPharm

CMIIT Young Investigator Award Session

  • Optimal [18]F-Misonidazole PET threshold to locate SCC7 tumor hypoxia using EPR pO2 as ground truth
  • Targeting Activated Fibroblasts for non-invasive detection of Lung Fibrosis
  • Bispecific INV721 antibody improves specific targeting in neuroblastoma to limit neuropathic pain
Show more CMIIT Young Investigator Award Session

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire